# Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

> **NCT05387603** · PHASE3 · RECRUITING · sponsor: **Lund University Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-DOTATOC
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05387603
- **Lead sponsor:** Lund University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387603, "Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05387603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*